Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arkansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arkansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arkansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Sarah Jewell (NPI 1508152471)

Field	Value
Entity Type	Individual
Organization	Sarah Jewell
Address	20 Baptist Health Dr Ste 100
City	Heber Springs
State	AR
ZIP	72543
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 20, 2011

Payer Source	Total Paid
Medicare	$2.7M
Medicaid	$0

Key Findings

This provider is effectively single‑payer: lifetime Medicare revenue is $2.7M and there is no Medicaid billing on file, so the practice’s public-payer footprint is concentrated in Medicare only. The NPI was enumerated 2011-06-20 (~15 years ago), indicating an established presence in the market.

Revenue is highly concentrated in a small set of high-cost oncology drugs: the precomputed top‑3 Medicare codes account for 54.3% of this provider’s total Medicare revenue, led by J9271 (31.1%), J9299 (14.2%), and J1561 (9.0%). This concentration signals that a majority of Medicare dollars come from a few infused or injected specialty therapies rather than dispersed office visit billing.

The code mix indicates an oncology infusion and diagnostic practice centered on checkpoint inhibitors and supportive biologics: J9271 (pembrolizumab), J9299 (nivolumab), and J1561 (immune globulin) are the top revenue drivers, and chemotherapy administration code 96413 appears among top items. Substantial billing for PET/CT (78815) and CT (74178) further supports a clinical model that combines systemic therapy with in‑house or closely coordinated imaging for staging and monitoring.

National competitive standing for the primary drug codes is modest to typical rather than dominant: J9271 ranks #493 of 1841 providers (73th percentile), J9299 ranks #248 of 505 (51th percentile), and J1561 ranks #62 of 180 (66th percentile), which collectively indicate routine but not market‑leading volumes for these agents at the national level. Several other biologic drug codes (for example J9173 and J9144) are present but sit at lower national percentiles, reinforcing a mid‑tier national footprint for specialty oncology drugs.

There are notable statistical outliers in non‑drug services that imply high local intensity of visits and imaging: 99215 is labeled an "extreme outlier" (511 claims, $127 avg paid/claim, $64.9K revenue; ranks #1833 of 145531 providers, 99th percentile) and 74178 is also an "extreme outlier" (241 claims, $175 avg paid/claim, $42.2K revenue; ranks #78 of 11397 providers, 99th percentile). These extreme‑percentile E/M and CT volumes, together with a notably above‑typical chemotherapy administration volume for 96413 (565 claims; ranks in the 93th percentile), suggest the practice manages a high acuity outpatient oncology population with frequent high‑complexity visits and imaging.

Imaging and radiopharmaceuticals contribute meaningful secondary revenue: 78815 (PET/CT) accounts for $188.4K (7.5% of Medicare revenue) across 189 claims at $997 avg paid/claim, and A9552 (FDG dose) appears with 205 claims and $31.6K revenue (1.3%). The presence of both high‑value imaging and associated radiotracer billing supports an integrated care pathway where staging and response assessment are billed alongside systemic therapy.

Ancillary diagnostics and supportive care are consistent with active oncology management: routine lab panels and blood work appear at high claim volumes and percentiles (80053: 1.9K claims, $10 avg, $18.6K revenue, 97th percentile; 85025: 2.2K claims, $8 avg, $17.2K revenue, 97th percentile), and growth‑factor biosimilars and supportive agents (Q5108, J0885, Q5115) are also billed. This pattern is consistent with an outpatient oncology practice that provides or coordinates frequent labs and supportive treatments to sustain infusion regimens.

Taken together, the provider presents as an established (~15 years) Medicare‑focused hematology/oncology clinician with revenue driven predominantly by high‑cost immunotherapy drugs and supported by unusually high E/M and imaging activity. For payer or network analysts, this profile points to a mid‑sized oncology practice with concentrated drug revenue, strong diagnostic/infusion support services, and minimal to no Medicaid participation.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

126 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	18,200	$40	$782.6K
J9299	Injection, nivolumab, 1 mg	14,860	$20	$356.6K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	5,930	$40	$225.3K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	190	$1,000	$188.4K
J9173	Injection, durvalumab, 10 mg	2,590	$60	$155.2K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	4,140	$40	$144.9K
J0897	Injection, denosumab, 1 mg	6,180	$20	$111.2K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	2,800	$30	$92.4K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	510	$130	$64.9K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	570	$90	$49.2K

Showing 1–10 of 126

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 126 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arkansas Distribution

Sarah Jewell — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arkansas

Full comparison — all codes billed, vs. state median

126 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	24	40	20,700	$40	$896.3K
J9299	18	30	15,660	$20	$432.9K
J9144	12	10	10,530	$40	$361.9K
J9173	2	10	5,110	$60	$310.2K
J1561	8	10	5,930	$40	$216.4K
Q5115	11	20	2,800	$30	$95.9K
J0897	42	160	2,580	$20	$89.7K
78815	31	100	90	$550	$83.7K
Q5118	8	10	2,110	$20	$64.3K
J0885	28	40	4,070	$10	$38K

Showing 1–10 of 126

Related Providers

Other providers that share a Tax Identification Number (TIN) with Sarah Jewell, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Baptist Health	AR	General Acute Care Hospital	$0	$16.4M
Baptist Health	AR	General Acute Care Hospital	$0	$14M
Baptist Health	AR	Critical Access Hospital	$0	$4.8M
Mcsa LLC	AR	General Acute Care Hospital	$0	$4.3M
Baptist Health	AR	Critical Access Hospital	$0	$3.7M
Baptist Health	AR	Rehabilitation Hospital	$0	$2.9M
Baptist Health	AR	General Acute Care Hospital	$0	$2.7M
Baptist Health	AR	Land Ambulance	$396K	$1.5M
Baptist Health	AR	Home Health Agency	$0	$1.8M
Arkansas Health Group	AR	Pulmonary Disease Physician	$0	$1.7M

Nearby Providers

Other providers in the same ZIP code as Sarah Jewell, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Community School Of Cleburne County	AR	Developmentally Disabled Services Day Training Agency	$0	$19.3M
Survival Flight Ems LLC	AR	Land Ambulance	$2.1M	$3.1M
Arcare	AR	Federally Qualified Health Center (FQHC)	$0	$3.6M
Eldercare Of Arkansas Iv, Inc.	AR	Assisted Living Facility	$0	$3M
United Methodist Children's Home, Inc.	AR	Adolescent and Children Mental Health Clinic/Center	$0	$1.7M
Aimee Widner	AR	Physical Medicine & Rehabilitation Physician	$210.3K	$45.1K
Jan Sharp	AR	Family Medicine Physician	$175.3K	$0
Granville Vaughan	AR	Family Medicine Physician	$134.9K	$0
Richard Matthews	AR	Physical Therapist	$133.5K	$0
Danny Lister	AR	Surgery Physician	$63.6K	$0

Sarah Jewell — Billing Profile & Reimbursement Data

Sign up for Sarah Jewell — Billing Profile & Reimbursement Data policy alerts

Sarah Jewell — Billing Profile & Reimbursement Data

Sign up for Sarah Jewell — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References